Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2015: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017 - 2016 - 2015 - 2014

September 2015 Scleroderma News

Corbus Pharmaceuticals Initiates Phase 2 Study Patient Enrollment of Resunab for Systemic Sclerosis. Corbus Pharmaceuticals recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Scleroderma News, 09/02/2015. (Also see Clinical Trials)

A Longitudinal Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis (SSc). Skin gene expression can be used effectively to monitor SSc skin disease change over time. PubMed, Arthritis Rheumatol, 08/03/2015. (Also see Diffuse Scleroderma and Skin Fibrosis)

Study Demonstrates Benefits of Medical Nutrition Therapy (MNT) Intervention in Systemic Sclerosis (SSc) Patients with Gastrointestinal Involvement (GI). Future studies should include direct measures of body composition and should seek to determine the durability of MNT on symptom improvement in a larger number of patients with SSc involving the GI tract. Scleroderma News, 07/27/2015. (Also see Gastrointestinal Involvement and Diet and Scleroderma)

Three-Year Study Reveales Functional Disability and Fatigue Scores Remain Stable in Systemic Sclerosis Patients. Although systemic sclerosis causes increasing disability and symptom aggravation over time, this study contributes to the growing idea that systemic sclerosis is not necessarily a progressive disease. Scleroderma News, 07/30/2015. (Also see Fatigue)

Temporomandibular Joint Disorder (TMJD) Found to Be a Common Condition in Systemic Sclerosis Patients. TMJD is a common condition in systemic sclerosis patients, and it correlates with disease severity. Scleroderma News, 07/24/2015. (Also see Temporomandibular Joint Disorder)

Novel Mechanism Contributing To Skin Fibrosis in Systemic Sclerosis Identified. The TGF–beta signaling pathway is strongly involved with systemic sclerosis pathogenesis. Scleroderma News, 07/31/2015. (Also see Skin Fibrosis)

Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers (DU) in Systemic Sclerosis (SSc). Anti–ETAR autoantibodies can be used together with the presence of current or past DU to identify patients with SSc who are at risk for the development of subsequent DU. PubMed, 08/01/2015. (Also see Digital Ulcers)

Epigenetics and systemic sclerosis. The environment can trigger epigenetic regulation that in turn establishes a molecular framework linking environmental exposures to genetics, leading to the disease process, possibly in a genetically predisposed host. PubMed, Semin Immunopathol, 07/11/2015. (Also see Causes of Scleroderma:Genetics)

Late nailfold videocapillaroscopy (NVC) patterns associated with hand calcinosis and acro-osteolysis in systemic sclerosis (SSc). Acro–osteolysis and calcinosis are independently associated with the late NVC pattern, and particularly with severe capillary loss. PubMed, Arthritis Care Res (Hoboken), 07/20/2015. (Also see Bone Resorption in SSc Calcinosis and Nailfold videocapillaroscopy)

A review on quality of life in systemic sclerosis (SSc). It is important for SSc patients to have an interdisciplinary approach towards their cognitive representations of the disease and what they value most. PubMed, Autoimmunity Reviews, 07/29/2015. (Also see Quality of Life with Scleroderma)

The risk of pulmonary embolism and deep venous thrombosis (VTE) in systemic sclerosis (SSc): A general population-based study. SSc patients are at a substantially increased risk of VTE and so increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted. PubMed, Arthritis Care   Research, 07/28/2015. (Also see Antiphospholipid Syndrome)

Go to Scleroderma Medical News: August 2015

United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.